Medical Director, Viral Hepatitis Programs & Center for Asian Health| Global Health Advisor
Cooperman Barnabas Medical Center | Hepatitis B Foundation
Florham Park, NJ, United States
Su Wang, MD, MPH, FACP is the Medical Director of Viral Hepatitis Programs & the Center for Asian Health at the Cooperman Barnabas Medical Center, RWJBarnabas Health. She serves as Global Health advisor for the Hepatitis B Foundation and was previously president of the World Hepatitis Alliance.
She has served as primary investigator for a number of viral hepatitis screening, vaccination & linkage-to-care studies sponsored by the US CDC and other funders. Dr. Wang has led primary care-based hepatitis B and C programs, community & hepatitis based screening initiatives, community based research and advocacy efforts.
Dr. Wang has served on a number of WHO guideline development committees including the ”Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy” and the “Interim guidance for country validation of viral hepatitis elimination.” She is a member of AASLD (American Association for the Study of Liver Diseases) and serves on the steering committee for the HBV Special Interest Group, the Viral Hepatitis Elimination Taskforce and is on the Patient Advisory Group. She serves on WHO's Global Validation Advisory Committee which supports country efforts of prevention of mother to child transmission (PMTCT) for triple elimination of HIV, syphilis and HBV.
She received her Medical Degree from the University of Miami and her Masters of Public Health from Johns Hopkins School of Public Health. Dr. Wang completed a combined Internal Medicine and Pediatric residency at Georgetown University Hospital and then served as an Epidemic Intelligence Service officer for the Centers for Disease Control and Prevention (CDC) at the US Food and Drug Administration (FDA). She was previously the Director of Hepatitis Programs at the Charles B. Wang Community Health Center in New York City.
Disclosure(s): Gilead Sciences, Inc: Grant/Research Support (Ongoing)
Friday, October 18, 2024
10:30 AM – 11:45 AM US PT